Matches in SemOpenAlex for { <https://semopenalex.org/work/W1875734482> ?p ?o ?g. }
- W1875734482 abstract "Background Eye disease due to herpes simplex virus (HSV) commonly presents as epithelial keratitis which, though usually self‐limiting, may persist or progress without treatment. Objectives To compare the relative effectiveness of antiviral agents, interferon, and corneal debridement in the treatment of HSV epithelial keratitis. Search methods We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (2014, Issue 12), PubMed (January 1946 to 31 December 2014), EMBASE (January 1980 to 31 December 2014), Latin American and Caribbean Health Sciences Literature Database (LILACS) (January 1982 to 31 December 2014), System for Information on Grey Literature in Europe (OpenGrey) (January 1995 to 31 December 2014), BIOSIS (January 1926 to 5 May 2014), Scopus (January 1966 to 31 December 2014), Japan Science and Technology Institute (J‐Global) (January 1975 to 31 December 2014), China National Knowledge Infrastructure (CNKI) (January 1979 to 31 December 2014), British Library's Electronic Table of Contents (Zetoc) (January 1993 to 7 May 2014). We looked for trials listed on the the metaRegister of Controlled Trials (www.controlled‐trials.com), ClinicalTrials.gov (www.clinicaltrials.gov), the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en), Chinese Clinical Trial Registry, the U.S. Food and Drug Administration (FDA) (www.fda.gov/), National Institute for Health and Clinical Excellence (NICE) (www.evidence.nhs.uk) and the European Medicines Agency (EMA) (www.ema.europa.eu/ema/) as of 31 December 2014. There were no language or date restrictions in the search for trials. We also culled literature digests and conference proceedings as of 15 April 2014. There were no language or date restrictions in the search for trials. Selection criteria Randomised and quasi‐randomised trials of HSV dendritic or geographic epithelial keratitis were included that reported the proportion of eyes healed at one week, two weeks, or both after enrolment. Data collection and analysis We tabulated data on study characteristics, risk of bias, and outcomes and used direct comparisons to estimate a risk ratio (RR) and, when feasible, a hazard ratio (HR) with a 95% confidence interval (CI). Heterogeneity was assessed by an inconsistency index. A multiple treatment comparison meta‐analysis consolidated direct and indirect comparisons of relative healing at 14 days. Main results One hundred thirty‐seven studies involving 8333 eyes met the inclusion criteria. Placebo‐controlled studies were heterogeneous in comparison with idoxuridine (RR 1.74; 95% CI 1.03 to 2.91) and few in number for vidarabine (RR 1.81; 95% CI 1.09 to 3.01), interferon (RR 1.32; 95% CI 1.06 to 1.64), and debridement. Vidarabine (RR 1.13; 95% CI 1.02 to 1.25), trifluridine (RR 1.30; 95% CI 1.18 to 1.43), acyclovir (RR 1.23; 95% CI 1.14 to 1.34), and brivudine (RR 1.34; 95% CI 1.18 to 1.51) were more effective than idoxuridine. Trifluridine (RR 1.17; 95% CI 1.03 to 1.32) and acyclovir (RR 1.11; 95% CI 1.03 to 1.19) were more effective than vidarabine. No significant differences in healing emerged among trifluridine, acyclovir, brivudine, and foscarnet although few studies compared brivudine or foscarnet with other antivirals. Any potential advantage of ganciclovir compared to acyclovir was mitigated by study heterogeneity and possible publication bias. Only one study evaluated the joint use of two topical antivirals. In a limited number of studies, oral acyclovir (RR 0.92; 95% CI 0.79 to 1.07) or the combination of oral acyclovir with a topical antiviral (RR 1.36; 95% CI 0.68 to 2.74) appeared as effective as a single topical antiviral agent. Compared to topical antiviral monotherapy, the combination of an antiviral with either interferon or debridement had inconsistent effects on expediting healing and improving outcome. Authors' conclusions Placebo‐controlled studies of HSV epithelial keratitis are limited to superseded interventions. Trifluridine and acyclovir are more effective than idoxuridine or vidarabine and similar in therapeutic effectiveness. Brivudine and foscarnet do not substantially differ in effectiveness from trifluridine or acyclovir. Ganciclovir is at least as effective as acyclovir. The addition of interferon to a nucleoside antiviral agent and the combination of debridement with antiviral treatment need to be further assessed to substantiate any possible advantage in healing." @default.
- W1875734482 created "2016-06-24" @default.
- W1875734482 creator A5016321396 @default.
- W1875734482 date "2015-01-09" @default.
- W1875734482 modified "2023-09-25" @default.
- W1875734482 title "Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis" @default.
- W1875734482 cites W134988173 @default.
- W1875734482 cites W147244789 @default.
- W1875734482 cites W1512657431 @default.
- W1875734482 cites W152087421 @default.
- W1875734482 cites W1552715487 @default.
- W1875734482 cites W1560106219 @default.
- W1875734482 cites W1562979910 @default.
- W1875734482 cites W1572560385 @default.
- W1875734482 cites W1575047830 @default.
- W1875734482 cites W1578496487 @default.
- W1875734482 cites W1583706370 @default.
- W1875734482 cites W1591880306 @default.
- W1875734482 cites W1593671348 @default.
- W1875734482 cites W1595237219 @default.
- W1875734482 cites W169511243 @default.
- W1875734482 cites W1753532689 @default.
- W1875734482 cites W1798676926 @default.
- W1875734482 cites W18002472 @default.
- W1875734482 cites W183754734 @default.
- W1875734482 cites W1875734482 @default.
- W1875734482 cites W187944343 @default.
- W1875734482 cites W188898467 @default.
- W1875734482 cites W1964938308 @default.
- W1875734482 cites W1964996269 @default.
- W1875734482 cites W1965179416 @default.
- W1875734482 cites W1966814352 @default.
- W1875734482 cites W1967587487 @default.
- W1875734482 cites W1968538214 @default.
- W1875734482 cites W1969648328 @default.
- W1875734482 cites W1970219767 @default.
- W1875734482 cites W1970341165 @default.
- W1875734482 cites W1970412040 @default.
- W1875734482 cites W1970660914 @default.
- W1875734482 cites W1971140896 @default.
- W1875734482 cites W1971506193 @default.
- W1875734482 cites W1972543205 @default.
- W1875734482 cites W1973630964 @default.
- W1875734482 cites W1975584609 @default.
- W1875734482 cites W1976934746 @default.
- W1875734482 cites W1977038326 @default.
- W1875734482 cites W1978978715 @default.
- W1875734482 cites W1980314652 @default.
- W1875734482 cites W1980813155 @default.
- W1875734482 cites W1981003683 @default.
- W1875734482 cites W1981743547 @default.
- W1875734482 cites W1982867573 @default.
- W1875734482 cites W1982993250 @default.
- W1875734482 cites W1988222604 @default.
- W1875734482 cites W1988449894 @default.
- W1875734482 cites W1992658931 @default.
- W1875734482 cites W1993212200 @default.
- W1875734482 cites W1993780656 @default.
- W1875734482 cites W1994142686 @default.
- W1875734482 cites W1994682730 @default.
- W1875734482 cites W1995305578 @default.
- W1875734482 cites W1995425060 @default.
- W1875734482 cites W1997020518 @default.
- W1875734482 cites W1998774456 @default.
- W1875734482 cites W1999204807 @default.
- W1875734482 cites W1999422047 @default.
- W1875734482 cites W1999987165 @default.
- W1875734482 cites W2000081122 @default.
- W1875734482 cites W2001595282 @default.
- W1875734482 cites W2001831808 @default.
- W1875734482 cites W2003555594 @default.
- W1875734482 cites W2003663083 @default.
- W1875734482 cites W2005947177 @default.
- W1875734482 cites W2006770417 @default.
- W1875734482 cites W2006892948 @default.
- W1875734482 cites W2006897878 @default.
- W1875734482 cites W2006958430 @default.
- W1875734482 cites W2007656614 @default.
- W1875734482 cites W2008660721 @default.
- W1875734482 cites W2010995130 @default.
- W1875734482 cites W2011608036 @default.
- W1875734482 cites W2012349170 @default.
- W1875734482 cites W2014379403 @default.
- W1875734482 cites W2016340173 @default.
- W1875734482 cites W2016350263 @default.
- W1875734482 cites W2016441801 @default.
- W1875734482 cites W2017943400 @default.
- W1875734482 cites W2017947682 @default.
- W1875734482 cites W2018546628 @default.
- W1875734482 cites W2018690866 @default.
- W1875734482 cites W2020235706 @default.
- W1875734482 cites W2020732215 @default.
- W1875734482 cites W2021165534 @default.
- W1875734482 cites W2021314445 @default.
- W1875734482 cites W2022410051 @default.
- W1875734482 cites W2022576490 @default.
- W1875734482 cites W2023192440 @default.
- W1875734482 cites W2025208565 @default.
- W1875734482 cites W2025493764 @default.
- W1875734482 cites W2026091981 @default.